Medical device development projects carry a built-in tension: engineering teams operate on schedules and deliverables, while quality teams operate on procedures and evidence. When these two streams run in parallel, quality becomes a downstream audit of engineering decisions already made. ISO 13485 clause 7.3 and FDA QMSR design control requirements exist precisely to prevent that pattern. They frame quality not as a review layer applied after the fact, but as a set of inputs, gates, and deliverables woven into the project itself.
In a project quality management approach, risk analysis begins before design outputs are drafted. Design reviews function as formal project gates: a team cannot advance a phase without documented review records, resolved action items, and updated risk assessments. Verification and validation are not activities scheduled “near the end.” They are planned deliverables with acceptance criteria defined during design inputs, traceable through the design history file.
Project changes complicate this picture significantly. A scope change, a supplier substitution, or a revised specification does not affect only the engineering timeline. It triggers change control procedures, requires risk file review, and may invalidate previously completed verification activities. Teams that lack a formal connection between project management and the quality system routinely discover this late, producing rework that delays both the project and regulatory submission readiness.
Regulatory submission readiness is itself a project quality outcome. Technical files for CE marking under EU MDR, 510(k) submissions, and PMA packages all require a coherent design history demonstrating that each project phase was controlled. Gaps in design review records, unresolved risk file versions, or missing validation rationales are submission blockers that originate in project execution, not in documentation work. Treating project milestones and regulatory milestones as the same artifact is the practical implication of ISO 13485 clause 7.3 compliance.
The whitepaper below details how qmsWrapper integrates quality activities directly into project execution so design control evidence builds continuously rather than at submission crunch.
